Pfenex (PFNX) announced the submission of its new drug application, or NDA, to the FDA seeking approval of PF708 for the treatment of osteoporosis. The application is submitted as a 505 NDA and references Eli Lilly’s (LLY) Forteo as the reference listed drug.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.